PURPOSE: The main purpose of the study was to provide quantitative data regarding survival and diagnostic delay. Mucopolysaccharidosis (MPS) type VII (OMIM 253220) is a progressive neurometabolic disorder caused by deficiency of the lysosomal enzyme β-glucuronidase (GUS). Hard clinical end points have not been quantitated Methods: We quantitatively analyzed published cases with MPS VII (N = 53/88 with sufficient data). Main outcome measures were onset of disease and survival. The role of biomarkers such as GUS residual enzyme activity and levels of storage material assessed as urinary excretion of glucosaminoglycans (GAG) as potential predictors of clinical outcomes were investigated. The analysis was conducted according to STROBE criteria. RESULTS: Median survival of the postnatally diagnosed population was up to 360 months . Median age of disease onset was the first day of life; median age at diagnosis was 11 months. Hydrops fetalis was frequent. Patients with residual GUS activity in fibroblasts more than 1.4% or urinary GAG excretion less than 602% of normal survived longer than patients with GUS enzyme activity below or GAG excretion above these thresholds. CONCLUSION: MPS VII has its disease onset prenatally. In the absence of a prenatal diagnosis, most cases are clinically apparent at birth. Our data corroborate a phenotype-biomarker association in MPS VII. The survival data characterize the natural history with important implications for therapeutic studies.Genet Med advance online publication 06 April 2017.
PURPOSE: The main purpose of the study was to provide quantitative data regarding survival and diagnostic delay. Mucopolysaccharidosis (MPS) type VII (OMIM 253220) is a progressive neurometabolic disorder caused by deficiency of the lysosomal enzyme β-glucuronidase (GUS). Hard clinical end points have not been quantitated Methods: We quantitatively analyzed published cases with MPS VII (N = 53/88 with sufficient data). Main outcome measures were onset of disease and survival. The role of biomarkers such as GUS residual enzyme activity and levels of storage material assessed as urinary excretion of glucosaminoglycans (GAG) as potential predictors of clinical outcomes were investigated. The analysis was conducted according to STROBE criteria. RESULTS: Median survival of the postnatally diagnosed population was up to 360 months . Median age of disease onset was the first day of life; median age at diagnosis was 11 months. Hydrops fetalis was frequent. Patients with residual GUS activity in fibroblasts more than 1.4% or urinary GAG excretion less than 602% of normal survived longer than patients with GUS enzyme activity below or GAG excretion above these thresholds. CONCLUSION: MPS VII has its disease onset prenatally. In the absence of a prenatal diagnosis, most cases are clinically apparent at birth. Our data corroborate a phenotype-biomarker association in MPS VII. The survival data characterize the natural history with important implications for therapeutic studies.Genet Med advance online publication 06 April 2017.
Authors: O Goker-Alpan; K S Hruska; E Orvisky; P S Kishnani; B K Stubblefield; R Schiffmann; E Sidransky Journal: J Med Genet Date: 2005-06 Impact factor: 6.318
Authors: Ainslie L K Derrick-Roberts; Carmen E Pyragius; Xenia M Kaidonis; Matilda R Jackson; Donald S Anson; Sharon Byers Journal: Hum Gene Ther Date: 2014-08-14 Impact factor: 5.695
Authors: Adriana M Montaño; Ngu Lock-Hock; Robert D Steiner; Brett H Graham; Marina Szlago; Robert Greenstein; Mercedes Pineda; Antonio Gonzalez-Meneses; Mahmut Çoker; Dennis Bartholomew; Mark S Sands; Raymond Wang; Roberto Giugliani; Alfons Macaya; Gregory Pastores; Anastasia K Ketko; Fatih Ezgü; Akemi Tanaka; Laila Arash; Michael Beck; Rena E Falk; Kaustuv Bhattacharya; José Franco; Klane K White; Grant A Mitchell; Loreta Cimbalistiene; Max Holtz; William S Sly Journal: J Med Genet Date: 2016-02-23 Impact factor: 6.318
Authors: Brittney L Gurda; Adrien De Guilhem De Lataillade; Peter Bell; Yanqing Zhu; Hongwei Yu; Ping Wang; Jessica Bagel; Charles H Vite; Tracey Sikora; Christian Hinderer; Roberto Calcedo; Alexander D Yox; Richard A Steet; Therese Ruane; Patricia O'Donnell; Guangping Gao; James M Wilson; Margret Casal; Katherine P Ponder; Mark E Haskins Journal: Mol Ther Date: 2015-10-08 Impact factor: 11.454
Authors: Huda B Al-Kouatly; Laura Felder; Mona M Makhamreh; Stephanie L Kass; Neeta L Vora; Vincenzo Berghella; Seth Berger; David A Wenger; Paola Luzi Journal: Prenat Diagn Date: 2020-03-20 Impact factor: 3.050
Authors: Roberto Giugliani; Anneliese Lopes Barth; Melissa Rossi Calvão Dumas; José Francisco da Silva Franco; Liane de Rosso Giuliani; Carlos Henrique Paiva Grangeiro; Dafne Dain Gandelman Horovitz; Chong Ae Kim; Emilia Katiane Embiruçu de Araújo Leão; Paula Frassinetti Vasconcelos de Medeiros; Diego Santana Chaves Geraldo Miguel; Maria Espírito Santo Almeida Moreira; Helena Maria Guimarães Pimentel Dos Santos; Luiz Carlos Santana da Silva; Luiz Roberto da Silva; Isabel Neves de Souza; Tatiele Nalin; Daniel Garcia Journal: Orphanet J Rare Dis Date: 2021-05-22 Impact factor: 4.123
Authors: Matthias Zielonka; Stefan Kölker; Florian Gleich; Nicolas Stützenberger; Sandesh C S Nagamani; Andrea L Gropman; Georg F Hoffmann; Sven F Garbade; Roland Posset Journal: Ann Clin Transl Neurol Date: 2019-08-30 Impact factor: 4.511
Authors: Sven F Garbade; Matthias Zielonka; Konstantin Mechler; Stefan Kölker; Georg F Hoffmann; Christian Staufner; Eugen Mengel; Markus Ries Journal: PLoS One Date: 2020-04-08 Impact factor: 3.240